Intercept Pharmaceuticals Inc EBITDA
What is the EBITDA of Intercept Pharmaceuticals Inc?
The EBITDA of Intercept Pharmaceuticals Inc is -$82.97
What is the definition of EBITDA?
EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
ttm (trailing twelve months)
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with ebitda similar to Intercept Pharmaceuticals Inc
- Hexagon Composites ASA has EBITDA of -kr83.92
- Aclaris Therapeutics has EBITDA of -$83.89
- Veejay Lakshmi Engineering Works has EBITDA of -₨83.83
- Ivanhoe Electric Inc has EBITDA of -$83.66
- House of Control AS has EBITDA of -kr83.19
- UroGen Pharma has EBITDA of -$83.15
- Intercept Pharmaceuticals Inc has EBITDA of -$82.97
- Prosperous Printing has EBITDA of -HKD$82.53
- McEwen Mining Inc has EBITDA of -$82.48
- Roadrunner Transportation Systems Inc has EBITDA of -$82.46
- theMaven has EBITDA of -$82.45
- Oil Country Tubular has EBITDA of -₨82.44
- Tijaria Polypipes has EBITDA of -₨82.37